Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
US-England World Cup game seen by 19.98M on US television
Bird flu prompts slaughter of 1.8M chickens in Nebraska
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
US-England World Cup game seen by 19.98M on US television
Bird flu prompts slaughter of 1.8M chickens in Nebraska
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
US-England World Cup game seen by 19.98M on US television
Bird flu prompts slaughter of 1.8M chickens in Nebraska
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
US-England World Cup game seen by 19.98M on US television
Bird flu prompts slaughter of 1.8M chickens in Nebraska
NASDAQ:REGN

Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

$736.23
+0.87 (+0.12%)
(As of 11/25/2022 04:00 PM ET)
Add
Compare
Today's Range
$728.61
$737.24
50-Day Range
$684.63
$759.91
52-Week Range
$538.01
$769.63
Volume
229,209 shs
Average Volume
639,110 shs
Market Capitalization
$80.18 billion
P/E Ratio
15.52
Dividend Yield
N/A
Price Target
$766.81

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.59 Rating Score
Upside/​Downside
4.2% Upside
$766.81 Price Target
Short Interest
Healthy
1.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
0.08mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$23.24 M Sold Last Quarter
Proj. Earnings Growth
-2.07%
From $38.08 to $37.29 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

409th out of 1,044 stocks

Pharmaceutical Preparations Industry

194th out of 510 stocks

REGN stock logo

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Stock News Headlines

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report? (REGN)
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
2 Top Biotech Stocks to Buy in November
Regeneron Pharmaceuticals Q3 Profit Decreases, but beats estimates
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings
11/04/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/03/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
10,368
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$766.81
High Stock Price Forecast
$970.00
Low Stock Price Forecast
$575.00
Forecasted Upside/Downside
+4.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.59
Research Coverage
22 Analysts

Profitability

Net Income
$8.08 billion
Pretax Margin
44.04%

Debt

Sales & Book Value

Annual Sales
$16.07 billion
Cash Flow
$80.82 per share
Book Value
$196.86 per share

Miscellaneous

Free Float
99,112,000
Market Cap
$80.18 billion
Optionable
Optionable
Beta
0.20

Social Links


Key Executives

  • Dr. Leonard S. Schleifer M.D.Dr. Leonard S. Schleifer M.D. (Age 69)
    Ph.D., Founder, Pres, CEO & Director
    Comp: $6.47M
  • Dr. George D. Yancopoulos M.D.Dr. George D. Yancopoulos M.D. (Age 62)
    Ph.D., Scientific Founder, Pres, Chief Scientific Officer & Director
    Comp: $6.4M
  • Mr. Robert E. Landry Jr.Mr. Robert E. Landry Jr. (Age 58)
    Exec. VP of Fin. & CFO
    Comp: $1.9M
  • Mr. Joseph J. LaRosaMr. Joseph J. LaRosa (Age 63)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $1.75M
  • Dr. Andrew J. Murphy Ph.D. (Age 63)
    Exec. VP of Research
    Comp: $1.57M
  • Mr. Daniel P. Van Plew (Age 49)
    Exec. VP and GM of Industrial Operations & Product Supply
    Comp: $1.77M
  • Ms. Patrice Gilooly
    Sr. VP of Quality Assurance & Operations
  • Mr. Christopher R. FenimoreMr. Christopher R. Fenimore (Age 51)
    Sr. VP, Head of Accounting & Controller
  • Mr. Gerald Underwood
    Sr. VP of Technical Operations
  • Mr. Bob McCowan
    Sr. VP of IT & Chief Information Officer













REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 2 sell ratings, 5 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGN shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price forecast for 2023?

22 Wall Street research analysts have issued 1 year target prices for Regeneron Pharmaceuticals' stock. Their REGN share price forecasts range from $575.00 to $970.00. On average, they anticipate the company's share price to reach $766.81 in the next twelve months. This suggests a possible upside of 4.2% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2022?

Regeneron Pharmaceuticals' stock was trading at $631.52 at the beginning of the year. Since then, REGN shares have increased by 16.6% and is now trading at $736.23.
View the best growth stocks for 2022 here
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 3rd 2023.
View our REGN earnings forecast
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported $15.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.81 by $5.56. The biopharmaceutical company had revenue of $3.45 billion for the quarter, compared to analysts' expectations of $2.80 billion. Regeneron Pharmaceuticals had a net margin of 39.17% and a trailing twelve-month return on equity of 31.16%. The company's revenue was up 50.5% compared to the same quarter last year. During the same quarter last year, the business posted $7.68 earnings per share.
Read the conference call transcript
.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.71%), Vanguard Group Inc. (7.94%), State Street Corp (4.64%), Price T Rowe Associates Inc. MD (1.61%), Putnam Investments LLC (1.01%) and Bank of New York Mellon Corp (0.94%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $736.23.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $80.18 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $47.43 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

The company employs 10,368 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 11/27/2022 by MarketBeat.com Staff